As of November 6, 2026, Vera Therapeutics, Inc. is a publicly traded company (Nasdaq: VERA); its largest reported holder is BlackRock, with 7.4% on Schedule 13G/A of July 30, 2026, then T. Rowe Price (6.4%). The largest insider holding is Patrick G. Enright, a director, with 3,602,475 shares (5.0% of shares outstanding), per Form 4 of December 15, 2025 (Schedule 13G/A, July 30, 2026).
Is this your company?
About to sign with, pay or invest in Vera Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Vera Therapeutics, Inc. a real, registered company?
- Vera Therapeutics, Inc. files with the SEC under CIK 1831828 (its SEC filings).
- Its shares are listed under the ticker VERA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Brisbane, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Vera Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-08-07).
Who are Vera Therapeutics, Inc.'s owners and officers?
Vera Therapeutics, Inc.: incorporated in Delaware; business address in Brisbane, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Kynam Capital Management, LP | 4.01% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.8% |
| Schedule 13G/A, 2026-07-30 | Blackrock, Inc. | 7.4% |
| Schedule 13G/A, 2026-05-15 | T. Rowe Price Associates, Inc. | 6.4% |
| Schedule 13G, 2026-04-01 | Point72 Asset Management, L.P. | 1.7% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-03-11 | Deep Track Capital, LP | 5.5% |
| Schedule 13D/A, 2026-03-05 | Sofinnova Venture Partners X, L.P. ("Svp X") | 4% |
| Schedule 13G/A, 2026-02-17 | T. Rowe Price Associates, Inc. | 7.7% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 4.1% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 5.03% |
| Schedule 13G/A, 2025-11-14 | T. Rowe Price Associates, Inc. | 5.7% |
Questions about who owns Vera Therapeutics, Inc.
Who owns Vera Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Vera Therapeutics, Inc.: Blackrock, Inc. (7.4%, Schedule 13G/A, filed 2026-07-30), T. Rowe Price Associates, Inc. (6.4%, Schedule 13G/A, filed 2026-05-15), State Street Corporation (5.8%, Schedule 13G, filed 2026-08-07) and Deep Track Capital, LP (5.5%, Schedule 13G, filed 2026-03-11).
Who are the largest shareholders of Vera Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Vera Therapeutics, Inc. on this page are Blackrock, Inc. (7.4%), T. Rowe Price Associates, Inc. (6.4%) and State Street Corporation (5.8%).
When did Blackrock, Inc. buy into Vera Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-07-30, reporting 7.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Vera Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vera Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Vera Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 3,602,475 shares (5.0% of shares outstanding), 5,882 held directly and 3,596,593 indirectly (Form 4, 2025-12-15).
- , the chief executive and president: 235,244 shares (0.33% of shares outstanding) (Form 4, 2026-09-17).
- , a director: 135,565 shares (0.19% of shares outstanding), 131,553 held directly and 4,012 indirectly (Form 4, 2024-10-30).
- , the chief financial officer: 119,181 shares (0.16% of shares outstanding), 114,181 held directly and 5,000 indirectly (Form 4, 2026-02-25).
- , the senior vice president and finance: 80,754 shares (0.11% of shares outstanding) (Form 4, 2026-09-14).
Shares outstanding: 72,298,770 as of 2026-10-29, from the company's latest SEC cover page.
How much has Vera Therapeutics, Inc. raised?
No fundraising or offering filing from Vera Therapeutics, Inc. is on file with us.
Keep reading
More on Vera Therapeutics, Inc. and the records around it.
Vera Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company: Jade Biosciences, Inc. (Mar 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Viridian Therapeutics, Inc. (Aug 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vera-therapeutics